Art. 4 Directive (EU) 1989/105

In forcesince 21 Dec 1988cited 27×
1.

In the event of a price freeze imposed on all medicinal products or on certain categories of medicinal products by the competent authorities of a Member State, that Member State shall carry out a review, at least once a year, to ascertain whether the macro-economic conditions justify that the freeze be continued unchanged Within 90 days of the start of this review, the competent authorities shall announce what increases or decreases in prices are being made, if any.

2.

In exceptional cases, a person who is the holder of a marketing authorization for a medicinal product may apply for a derogation from a price freeze if this is justified by particular reasons. The application shall contain an adequate statement of these reasons. Member States shall ensure that a reasoned decision on any such application is adopted and communicated to the applicant within 90 days. If the information supporting the application is inadequate, the competent authorities shall forthwith notify the applicant of what detailed additional information is required and take their final decision within 90 days of receipt of this additional information. Should the derogation be granted, the competent authorities shall forthwith publish an announcement of the price increase allowed.

Should there be an exceptional number of applications, the period may be extended once only for a further 60 days. The applicant shall be notified of such extension before the expiry of the initial period.

The 10 that are cited most themselves, of 27.

  • Judgment of the Court (Fourth Chamber) of 2 April 2009. A. Menarini Industrie Farmaceutiche Riunite Srl and Others v Ministero della Salute Decisioninterprets

    These references for a preliminary ruling concern the interpretation of Article 4 of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and …

    2 Apr 2009 · 62007CJ0352

  • SGB 5130aLaw

    … der Abschläge nach den Absätzen 1, 1a, 1b, 3a, 3e und 3f nach Maßgabe oder in entsprechender Anwendung des Artikels 4 der Richtlinie 89/105/EWG in der Fassung vom 21. Dezember 1988 die Abschläge durch Rechtsverordnung mit Zustimmung …

  • BVerfG, Nichtannahmebeschluss vom 23. August 2010 - 1 BvR 2002/10Decision

    … hat nach einer Überprüfung der Erforderlichkeit der Abschläge nach den Absätzen 1, 1a und 3a nach Maßgabe des Artikels 4 der Richtlinie 89/105/EWGdes Rates vom 21. Dezember 1988 betreffend die Transparenz von Maßnahmen zur Regelung …

    23 Aug 2010 · KVRE389751001

  • Judgment of the Court (Seventh Chamber) of 22 December 2022. Syndicat Les Entreprises du Médicament (LEEM) v Ministre des Solidarités et de Decisioninterprets

    This request for a preliminary ruling concerns the interpretation of Article 4 of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and …

    22 Dec 2022 · 62022CJ0020

  • BSG, Urteil vom 25. Oktober 2018 - B 3 KR 10/16 RDecision

    25 Oct 2018 · KSRE148810218

  • Decision_act (EU) 2015/13001Law

    … том V на германския Кодекс за социално осигуряване във връзка с член 4 от Директива 89/105/ЕИО, е съвместима с вътрешния пазар съгласно …

  • Judgment of the Court (Third Chamber) of 14 January 2010. Association générale de l’industrie du médicament (AGIM) ASBL and Others (C-471/07Decisioninterprets

    … Article 4(1) of Directive 89/105 must be interpreted as not being, so far as its subject-matter is concerned, sufficiently precise for an individual to be able to rely on it before a national court against a Member State. 3. Article 4(1) …

    14 Jan 2010 · 62007CJ0471

  • BVerfG, Beschluss vom 7. Mai 2025 - 1 BvR 1507/23 u.a.Decision

    (4) Auch für das Preismoratorium sieht § 130a Abs. 4 Satz 2 SGB V basierend auf Art. 4 der Richtlinie 89/105/EWG des Rates vom 21. Dezember 1988 einen Ausnahmeantrag bei Vorliegen besonderer Gründe vor, über den das Bundesamt für …

    7 May 2025 · KVRE462432501

  • Ordonnance du Tribunal (septième chambre) du 19 avril 2018. Allergopharma GmbH & Co. KG contre Commission européenne.Decision

    Sowohl der Herstellerabschlag als auch das Preismoratorium hätten einen „Preisstopp“ im Sinne des Art. 4 Abs. 1 der Richtlinie 89/105/EWG des Rates vom 21. Dezember 1988 betreffend die Transparenz von Maßnahmen zur Regelung der …

    19 Apr 2018 · 62015TO0354(02)

  • BSG, Urteil vom 3. Mai 2018 - B 3 KR 7/17 RDecision

    3 May 2018 · KSRE147820218